Clinical Trial Update: DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for DEPLETHINK (NKR-2) reporting Phase 1/Phase 2 results in AML and MDS; trial status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• NKR-2

Snippet

Sponsor: Celyad Oncology SA | Conditions: AML, MDS | Phase 1, Phase 2 | Status: COMPLETED